ABBV vs. DOCS: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ABBV and DOCS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | ABBV | DOCS |
|---|---|---|
| Company Name | AbbVie Inc. | Doximity, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Technology |
| Market Capitalization | 369.48 billion USD | 12.69 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | January 2, 2013 | June 24, 2021 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of ABBV and DOCS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | ABBV | DOCS |
|---|---|---|
| 5-Day Price Return | 2.18% | 2.75% |
| 13-Week Price Return | 12.62% | 33.48% |
| 26-Week Price Return | 8.12% | -13.08% |
| 52-Week Price Return | 6.24% | 85.95% |
| Month-to-Date Return | 10.65% | 15.30% |
| Year-to-Date Return | 17.70% | 26.88% |
| 10-Day Avg. Volume | 4.64M | 1.65M |
| 3-Month Avg. Volume | 6.39M | 2.21M |
| 3-Month Volatility | 19.56% | 46.07% |
| Beta | 0.49 | 1.39 |
Profitability
Return on Equity (TTM)
ABBV
95.59%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
ABBV’s Return on Equity of 95.59% is exceptionally high, placing it well beyond the typical range for the Biotechnology industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
DOCS
22.38%
Health Care Technology Industry
- Max
- 47.95%
- Q3
- 35.17%
- Median
- 13.74%
- Q1
- 11.05%
- Min
- 11.05%
DOCS’s Return on Equity of 22.38% is on par with the norm for the Health Care Technology industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
ABBV
6.45%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
ABBV’s Net Profit Margin of 6.45% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.
DOCS
39.13%
Health Care Technology Industry
- Max
- 51.50%
- Q3
- 45.32%
- Median
- 27.34%
- Q1
- 14.21%
- Min
- 14.21%
DOCS’s Net Profit Margin of 39.13% is aligned with the median group of its peers in the Health Care Technology industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
ABBV
18.80%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
ABBV’s Operating Profit Margin of 18.80% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.
DOCS
39.94%
Health Care Technology Industry
- Max
- 73.15%
- Q3
- 56.55%
- Median
- 26.97%
- Q1
- 22.10%
- Min
- 22.10%
DOCS’s Operating Profit Margin of 39.94% is around the midpoint for the Health Care Technology industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | ABBV | DOCS |
|---|---|---|
| Return on Equity (TTM) | 95.59% | 22.38% |
| Return on Assets (TTM) | 2.73% | 19.29% |
| Net Profit Margin (TTM) | 6.45% | 39.13% |
| Operating Profit Margin (TTM) | 18.80% | 39.94% |
| Gross Profit Margin (TTM) | 70.93% | 90.20% |
Financial Strength
Current Ratio (MRQ)
ABBV
0.74
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
ABBV’s Current Ratio of 0.74 is notably low, falling beneath the typical range for the Biotechnology industry. This suggests a heightened liquidity risk and could indicate potential challenges in meeting its short-term obligations.
DOCS
6.97
Health Care Technology Industry
- Max
- 7.04
- Q3
- 7.01
- Median
- 4.60
- Q1
- 2.96
- Min
- 0.31
DOCS’s Current Ratio of 6.97 aligns with the median group of the Health Care Technology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
ABBV
49.22
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
With a Debt-to-Equity Ratio of 49.22, ABBV operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
DOCS
0.00
Health Care Technology Industry
- Max
- 0.06
- Q3
- 0.05
- Median
- 0.01
- Q1
- 0.00
- Min
- 0.00
Falling into the lower quartile for the Health Care Technology industry, DOCS’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio (TTM)
ABBV
2.70
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
ABBV’s Interest Coverage Ratio of 2.70 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
DOCS
--
Health Care Technology Industry
- Max
- 224.12
- Q3
- 222.84
- Median
- 219.00
- Q1
- 181.50
- Min
- 169.00
Interest Coverage Ratio data for DOCS is currently unavailable.
Financial Strength at a Glance
| Symbol | ABBV | DOCS |
|---|---|---|
| Current Ratio (MRQ) | 0.74 | 6.97 |
| Quick Ratio (MRQ) | 0.48 | 6.73 |
| Debt-to-Equity Ratio (MRQ) | 49.22 | 0.00 |
| Interest Coverage Ratio (TTM) | 2.70 | -- |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
ABBV
3.11%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ABBV’s Dividend Yield of 3.11% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.
DOCS
0.00%
Health Care Technology Industry
- Max
- 1.12%
- Q3
- 0.62%
- Median
- 0.12%
- Q1
- 0.00%
- Min
- 0.00%
DOCS currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
ABBV
226.84%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
At 226.84%, ABBV’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
DOCS
0.00%
Health Care Technology Industry
- Max
- 101.92%
- Q3
- 72.22%
- Median
- 42.51%
- Q1
- 0.00%
- Min
- 0.00%
DOCS has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | ABBV | DOCS |
|---|---|---|
| Dividend Yield (TTM) | 3.11% | 0.00% |
| Dividend Payout Ratio (TTM) | 226.84% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
ABBV
96.80
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
At 96.80, ABBV’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Biotechnology industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
DOCS
54.05
Health Care Technology Industry
- Max
- 343.51
- Q3
- 272.61
- Median
- 54.67
- Q1
- 36.04
- Min
- 31.57
DOCS’s P/E Ratio of 54.05 is within the middle range for the Health Care Technology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
ABBV
6.24
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
ABBV’s P/S Ratio of 6.24 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
DOCS
21.15
Health Care Technology Industry
- Max
- 176.90
- Q3
- 98.12
- Median
- 16.38
- Q1
- 4.49
- Min
- 0.00
DOCS’s P/S Ratio of 21.15 aligns with the market consensus for the Health Care Technology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
ABBV
261.01
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
At 261.01, ABBV’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
DOCS
10.06
Health Care Technology Industry
- Max
- 117.60
- Q3
- 90.72
- Median
- 8.09
- Q1
- 3.83
- Min
- 3.06
DOCS’s P/B Ratio of 10.06 is within the conventional range for the Health Care Technology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | ABBV | DOCS |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 96.80 | 54.05 |
| Price-to-Sales Ratio (TTM) | 6.24 | 21.15 |
| Price-to-Book Ratio (MRQ) | 261.01 | 10.06 |
| Price-to-Free Cash Flow Ratio (TTM) | 19.97 | 45.22 |